Tuesday 13 October 2026
Export AUTL’s income statement to Excel — free account
Autolus Therapeutics PLC Sponsored ADR
AUTL Healthcare Biotechnology
In the quarter to June 2026, revenue grew 118.4%, EPS grew 16.7% and free cash flow grew 67.6%, each against the same quarter a year earlier.
1.60
0.14
−8.05%
Follow AUTL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
8.48 | 7.03 | 3.97 | 3.63 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.39) | (7.87) | (5.62) | (16.99) | |
P/B ratio |
1.63 | 2.97 | 3.37 | 5.69 | |
Price to Tangible BV |
1.77 | 3.35 | 4.09 | 7.56 | |
EV/Sales |
2.24 | 3.90 | 2.19 | 2.56 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.45) | (1.04) | (0.74) | (1.33) | |
EV/FCF |
(0.37) | (0.91) | (0.66) | (1.18) | |
Quick Ratio |
4.83 | 4.44 | 4.07 | 3.60 | |
Current Ratio |
6.19 | 5.94 | 5.80 | 4.89 | |
Net Debt/EBITDA |
5.34 | 3.37 | 4.06 | 3.04 | |
Debt/Assets |
0.00% | 11.34% | 0.00% | 15.76% | |
Debt/Equity |
0.00 | 0.38 | 0.00 | 1.04 | |
Asset Turnover |
0.07 | 0.11 | 0.15 | 0.19 | |
Operating CF/Net income |
0.86 | 0.75 | 0.91 | 0.64 | |
Capex/Depreciation |
(4.92) | 0.34 | (1.00) | (0.34) | |
Interest Coverage |
(6.81) | (3.17) | (5.35) | 16.39 | |
Research and Development Expense of Revenue |
131.60% | 146.70% | 80.90% | 61.06% | |
Selling, General and Administrative Expense of Revenue |
171.18% | 147.36% | 152.39% | 90.09% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
18.09% | 14.18% | 13.60% | 10.06% | |
Graham Net Nets |
0.27 | 0.05 | (0.13) | (0.19) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(50.92%) | (54.27%) | (78.99%) | (66.25%) | |
Free Cash Flow Yield |
(70.72%) | (61.13%) | (83.85%) | (59.62%) | |
Revenue per Share |
0.08 | 0.09 | 0.10 | 0.17 | |
Operating CF per Share |
(0.26) | (0.25) | (0.25) | (0.09) | |
Capex per Share |
(0.05) | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.30) | (0.25) | (0.26) | (0.10) | |
Cash per Share |
1.39 | 1.14 | 0.87 | 0.76 | |
Shareholders Equity per Share |
1.00 | 0.67 | 0.41 | 0.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.00 | 0.67 | 0.41 | 0.28 | |
Free Cash Flow |
(80.40) | (66.44) | (68.00) | (25.98) | |
Working Capital |
431.51 | 362.48 | 305.24 | 267.30 | |
Capital Expenditures |
(12.50) | 0.89 | (2.69) | (0.91) | |
Net Current Asset Value |
118.08 | 24.98 | (49.40) | (82.30) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.59 | (0.04) | 0.10 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
37.28 | 12.02 | 20.99 | 35.52 | |
Average Payables |
6.19 | 2.53 | 3.16 | 3.39 | |
Average Inventory |
— | 18.67 | 23.94 | 28.69 | |
Average Assets |
744.72 | 685.90 | 636.70 | 607.10 | |
Average Common Equity |
371.21 | 302.73 | 239.97 | 210.65 |
Columns are period end dates · fundamentals updated 28 Sep 2026